Glecirasib
Product Specifications
UNSPSC Description
Glecirasib (Compound 1-2; JAB-21822) is an orally active and potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer[1][2][3][4].
Target Antigen
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein;MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/glecirasib.html
Purity
98.89
Solubility
10 mM in DMSO
Smiles
N#CC1=C(N2CCN(CC2)C(C=C)=O)C3=C(N=C(C4=C(N)C(F)=C(F)C(F)=C4F)C(Cl)=C3)N(C5=C(C)C=CN=C5C(C)C)C1=O
Molecular Weight
640.03
References & Citations
[1]Amin LI, et al. Kras mutant protein inhibitors. Patent WO2021121367A1.|[2]Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors[J]. 2024.|[3]Ma C, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. J Med Chem. 2024 Aug 22;67(16):13534-13549. |[4]Fuerst M L. Glecirasib Induces Promising Efficacy in Patients With Advanced Lung Cancer[J]. 2024.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-143589/Glecirasib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-143589/Glecirasib-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2657613-87-9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2054940-06 5x 5 mL
Cy3-Linked Polyclonal Antibody to Adenylate Cyclase 4 (ADCY4)
Ask
View Details